home / stock / mbrx / mbrx news

MBRX News and Press, Moleculin Biotech Inc. From 05/27/20

Stock Information
Company Name: Moleculin Biotech Inc.
Stock Symbol: MBRX
Market: NASDAQ
Website: moleculin.com
Menu
MBRX MBRX Quote MBRX Short MBRX News MBRX Articles MBRX Message Board
Get MBRX Alerts

News, Short Squeeze, Breakout and More Instantly...
MBRX - Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

HOUSTON , May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification...
MBRX - Nasdaq Scheduled Resumption in Moleculin Biotech, Inc.

NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28, 2020, at 7:00 a.m. Eastern Time.  Trading in the company’s stock was halted on M...

MBRX - Moleculin Provides Update on Coronavirus Drug Development

HOUSTON , May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Adminis...

MBRX - Nasdaq Halts Moleculin Biotech Inc.

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional information requested" from the company. Trading in the company’s stock had been halted...
MBRX - Moleculin Announces Nasdaq Trading Halt Pending Receipt of Additional Information

HOUSTON , May 18, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of ...

MBRX - Moleculin Provides Additional Comments Regarding Trading Halt

HOUSTON , May 11, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1 st , ...

MBRX - Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

HOUSTON , May 8, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020 An...
MBRX - Moleculin Announces Trading Halt

HOUSTON , May 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced securities of the Company have been place...

MBRX - Moleculin to Speak on COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference

HOUSTON , April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Exe...

MBRX - WPD Pharmaceutical's Annamycin Drug Approved for Accelerated European Clinical Trial

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company is pleased to announce that through its license partner, Moleculin Biotech, Inc...
Previous 10 Next 10